Evidence map›Paper›PMID 28265288›Full record

ArticleStem cells international2017

Intravenous Administration of Adipose-Derived Stem Cell Protein Extracts Improves Neurological Deficits in a Rat Model of Stroke.

Kai Zhao, Rui Li, Changcong Gu, Long Liu, Yulong Jia, Xize Guo, Wanping Zhang, Chunying Pei, Linlu Tian, Bo Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kai ZhaoDepartment of Neurosurgery, The First Affiliate Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Rui LiNeuroinflammation Unit, Montreal Neurological Institute, McGill University, Montreal, QC, Canada H3A 2B4.
Changcong GuDepartment of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Long LiuDepartment of Neurosurgery, The First Affiliate Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Yulong JiaDepartment of Neurosurgery, The First Affiliate Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.
Xize GuoDepartment of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Wanping ZhangDepartment of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Chunying PeiDepartment of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Linlu TianDepartment of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Bo LiDepartment of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China.
Jianrong JiaDepartment of Neurosurgery, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150001, China.
Huakun ChengDepartment of Neurosurgery, Heilongjiang Provincial Hospital, Harbin, Heilongjiang 150001, China.
Hongwei XuDepartment of Immunology, Harbin Medical University, Harbin, Heilongjiang 150086, China.ORCID 0000-0001-5763-3894
Lixian LiDepartment of Neurosurgery, The First Affiliate Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.ORCID 0000-0003-4353-2229

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of adipose-derived stem cell (ADSC) substantially improves the neurological deficits during stroke by reducing neuronal injury, limiting proinflammatory immune responses, and promoting neuronal repair, which makes ADSC-based therapy an attractive approach for treating stroke. However, the potential risk of tumorigenicity and low survival rate of the implanted cells limit the clinical use of ADSC. Cell-free extracts from ADSC (ADSC-E) may be a feasible approach that could overcome these limitations. Here, we aim to explore the potential usage of ADSC-E in treating rat transient middle cerebral artery occlusion (tMCAO). We demonstrated that intravenous (IV) injection of ADSC-E remarkably reduces the ischemic lesion and number of apoptotic neurons as compared to other control groups. Although ADSC and ADSC-E treatment results in a similar degree of a long-term clinical beneficial outcome, the dynamics between two ADSC-based therapies are different. While the injection of ADSC leads to a relatively mild but prolonged therapeutic effect, the administration of ADSC-E results in a fast and pronounced clinical improvement which was associated with a unique change in the molecular signature suggesting that potential mechanisms underlying different therapeutic approach may be different. Together these data provide translational evidence for using protein extracts from ADSC for treating stroke.

Identifiers

PMID28265288
PMCPMC5318632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.